Diclofenaco Pensa is a Nonsteroidal Anti-Inflammatory Drug (NSAID) whose primary role is to provide supportive symptomatic relief across conditions marked by symptoms related to physical discomfort, swelling, and inflammatory states. Therapeutic applications include inflammatory rheumatism and acute pain states with an inflammatory component.

The medication is commonly used to help manage the symptom clusters associated with chronic inflammatory joint conditions like Osteoarthritis and Rheumatoid Arthritis, and acute pain from post-traumatic injuries or postoperative discomfort. It also is applied in addressing episodic pain manifestations such as acute migraine attacks and primary dysmenorrhea. It plays a role in managing symptoms related to systemic imbalance, such as fever. The objective of use is to assist with easing the overall symptom load and supporting patients during episodes of heightened discomfort.

---

Easing Pain and Stiffness

This medicine contributes to easing discomfort during periods of heightened symptoms and assists with supporting functional stability, particularly in contexts where joint pain and inflammation interfere with routine activities. It is applied in clinical settings that involve acute or unstable symptom patterns, offering support during challenging symptomatic phases.

Quick Fact: Focus on Key Symptoms	Description
Pain Intensity	Relevant for addressing symptoms of physical discomfort and acute symptomatic episodes where symptoms may intensify temporarily.
Inflammation	Relevant for managing symptoms related to swelling and inflammatory states.
Episodic Relief	Is applied in addressing symptoms associated with acute or episodic changes.
Systemic Support	Plays a role in managing symptoms related to fever.

Regulatory References

1. Therapeutic Goods Administration (TGA) safety review

Who Can and Cannot Use Diclofenaco Pensa?

This section summarizes the official eligibility profile for Diclofenaco Pensa, an NSAID, as defined in regulatory documentation. Eligibility is primarily determined by the absence of specific health conditions, physiological states, or surgical contexts.

---

Do Not Use (Contraindications):

Use of this medicine is strictly prohibited for individuals with:

• Hypersensitivity or Allergy: A history of asthma, hives (urticaria), acute rhinitis, or swelling (angioedema) after taking diclofenac, aspirin, or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
• Gastrointestinal Disease: Active stomach/intestinal ulcers, bleeding, or perforation, or a history of recurrent peptic ulcer/hemorrhage.
• Severe Organ Impairment: Established severe heart failure (NYHA Class II–IV), ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, or severe hepatic or renal failure.
• Surgical Context: Pain relief following coronary artery bypass graft (CABG) surgery.
• Pregnancy: During the third trimester of pregnancy.

---

Restricted or Special Consideration Use:

• Age: Generally not recommended for children and adolescents under 14 years of age.
• Organ Function: Patients with mild-to-moderate renal or hepatic impairment and the elderly require careful monitoring and must use the lowest effective dose for the shortest duration.

Diclofenaco Pensa Interactions with other medicines and products

Co-administration of Diclofenaco Pensa (Diclofenac) with certain medicines and substances is restricted due to documented interaction risks. Concomitant use with other systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or analgesic doses of Aspirin should be avoided due to the increased risk of serious gastrointestinal adverse events.

---

Clinically Significant Interactions

Interacting Substance/Class	Official Interaction Outcome
Anticoagulants and Antiplatelet Agents	Synergistic increase in the risk of serious bleeding.
ACE Inhibitors and ARBs	May diminish the antihypertensive effect and, in elderly or renally impaired patients, cause deterioration of renal function, including acute renal failure.
Lithium and Methotrexate	Diclofenac may increase the plasma concentration of these medicines by reducing their renal clearance, leading to potential toxicity.
Voriconazole (CYP Inhibitor)	Documented to significantly increase Diclofenac exposure due to inhibition of metabolic pathways.
Diuretics	Can reduce the natriuretic and diuretic efficacy.

---

Other Restrictions and Pharmacodynamic Effects: The consumption of alcohol is documented to increase the risk for serious gastrointestinal bleeding. Herbal products such as Ginkgo biloba or Ginseng may also potentiate bleeding risk. For Diclofenac potassium formulations, administration with food may result in reduced absorption and effectiveness, constituting a documented administration-timing restriction.

Blocking the Eicosanoid Inflammatory Cascade

Diclofenaco Pensa acts as an inhibitor of cyclooxygenase (COX) enzymes, demonstrating a preferential affinity for COX-2, which is generated at sites of cellular injury. This action interrupts the arachidonic acid cascade, blocking the synthesis of prostaglandins—the chemical mediators that sensitize pain receptors and initiate tissue inflammation. This suppression results in a reduction of excessive mediator activity, influencing the activity state within the inflammatory pathways.

Dual Modulation of Pain Signal Transmission

The mechanism regulates overactive pain signaling both locally and centrally. By decreasing prostaglandins at the injury site (periphery), the drug directly reduces the over-excitation of sensory nerves. Furthermore, it exerts a distinct modulatory effect within the Central Nervous System (CNS), dampening the transmission and amplification of pain signals in the spinal cord. This modulation results in defined physiological adjustments within the targeted pathways.

Resetting the Central Thermoregulatory Set Point

The inhibition of prostaglandin synthesis affects the hypothalamus—the brain's thermal regulatory center. The drug's molecular action suppresses the formation of fever-inducing prostaglandins (PGE2) in this area, directly influencing the body's core temperature regulation. This action influences the processes driven by specific signaling patterns, resulting in the normalization of an elevated temperature set point.

How to Use Diclofenac (Diclofenaco Pensa)

This section outlines instructions for using Diclofenac formulations, detailing administration methods, dosing schedules, and preparation requirements.

---

Administration Methods and Routes

Diclofenac is available in multiple forms, which determines the method of use. The routes of administration include Oral, Topical (on the skin), Rectal (suppository), and Parenteral (intramuscular or intravenous injection).

---

General Dosing and Frequency

Dosage Form	Example Frequency	Maximum Daily Dose
Oral (Immediate/Delayed Release)	Two to three times daily	Generally 150 mg
Oral (Extended Release)	Once daily	Typically 100 mg
IM/IV Injection	Once or twice daily	150 mg (for up to two days)
Topical Gel (2.32%)	Two times daily	8 g of gel

The lowest effective dose for the shortest duration necessary to manage the condition is utilized.

Preparation and Procedural Rules

Oral forms such as delayed-release or extended-release tablets are designed to be swallowed whole and are not to be crushed, chewed, or broken. For example, oral powder packets are mixed with a small amount of water only and taken immediately on an empty stomach. For Intramuscular (IM) injection, the dose is administered by deep intragluteal injection, and the injection site is alternated if multiple daily injections are required. Intravenous (IV) infusion requires prior dilution and buffering with sodium bicarbonate solution and is administered as an infusion over a minimum of 30 minutes, rather than as a rapid bolus. Topical gels are applied thinly and rubbed gently into intact skin; hands are washed immediately afterward unless the hands are the area being treated.

Research evidence / Overview of Studies for Diclofenaco Pensa

This section describes the research base and regulatory evidence used to characterize the medicine, focusing on what studies were conducted, which outcomes were measured, and what remains uncertain. This information is a non-advisory overview and does not offer individual medical guidance.

---

Evidence for Symptom Management in Chronic Inflammatory Joint Conditions

The research base for Diclofenaco Pensa in conditions like Osteoarthritis (OA) and Rheumatoid Arthritis (RA) primarily relies on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies involved adult and older adult populations with established joint conditions. Researchers monitored outcomes related to physical discomfort and daily functioning using standardized scores. Studies reported measurements of differences in symptom intensity and functional scores across the observed populations, often compared to a placebo or other standard medications.

Evidence for Relief in Acute Pain States

Diclofenaco Pensa was evaluated in numerous short-course RCTs focused on research contexts involving acute pain states, such as post-traumatic injuries or postoperative discomfort. Key outcomes monitored included the measurement of time until a reduction in pain was reported, maximum pain intensity reduction, and the documentation of the frequency of requiring supplementary pain medication. Research reports changes measured during the study period for outcomes capturing phases of heightened symptom activity.

Evidence for Episodic Pain Conditions

Studies have investigated Diclofenaco Pensa in research contexts involving conditions presenting with cycles of stability and flare-ups, specifically Primary Dysmenorrhea and the acute management of Migraine attacks. Research was designed to monitor responses in adult populations during episodes where symptoms become more noticeable. Outcomes examined included the achievement of complete pain freedom at defined early time points and the resolution of associated symptoms.

Long-Term Studies and Follow-up Duration

While research for acute pain involves very short-term follow-up, core efficacy RCTs for chronic conditions often had follow-up durations that were limited to a few weeks. Although extended observational studies have monitored patients for longer periods, evidence is limited for long-term outcomes regarding the durability of patient-reported effects over many years of continuous use. The available evidence for long-term symptom patterns relies primarily on observational data.

Research in Special Populations

Studies were primarily conducted in adults and older adults. Data are still emerging for certain subgroups. For instance, evidence is limited for use in children or adolescents as studies have focused almost exclusively on adult populations. Research for patients with severe, complex pre-existing conditions is often sparse, meaning the results apply only to the specific populations studied in the trials.

What Remains Uncertain in the Research Record

The formal scientific review highlights areas where evidence is still developing. Knowledge gaps include limited information for long-term functional status and durability of effect due to the limited follow-up durations of many trials. Evidence quality varies across studies, and subgroup findings are uncertain, as research describes group patterns, not personal outcomes.

Key Studies & References

1. Diclofenac Oral (MedlinePlus Drug Information)
2. Medicines Safety Review: Diclofenac (Therapeutic Goods Administration - TGA)

Common questions about Diclofenaco Pensa (FAQ)

---

Q: How quickly should I expect Diclofenaco Pensa to start reducing pain?

A: Official information indicates that the absorption of oral diclofenac may be delayed, particularly when taken with food. While studies measure the time until pain relief is reported, the exact onset can be variable and is influenced by the specific formulation being used.

---

Q: How long does the pain-relieving effect of Diclofenaco Pensa typically last?

A: Pharmacokinetic studies show that the medicine's half-life—the time it takes for half of the drug to be eliminated from the plasma—is short, typically 1 to 2 hours. The continued effect is maintained through the prescribed dosing schedule.

---

Q: Can Diclofenaco Pensa cause stomach upset, and is it a common side effect?

A: Yes, regulatory product information lists gastrointestinal disturbances, including nausea, dyspepsia (indigestion), and abdominal pain, as common side effects. These effects typically occur in 1% to 10% of patients.

---

Q: Is it normal to feel a slight headache when starting Diclofenaco Pensa?

A: According to official documentation, headache is classified as a common adverse reaction associated with the use of the medicine. This means it has been reported in 1% to 10% of individuals during clinical use.

---

Q: Do people generally experience drowsiness while taking Diclofenaco Pensa?

A: Yes, dizziness, vertigo, and drowsiness (somnolence) are listed as possible side effects in the official safety profile. Individuals may experience these effects while using the medicine.

---

Q: Can Diclofenaco Pensa interact with herbal supplements?

A: Official warnings advise that certain herbal products, such as Ginkgo biloba and Ginseng, may increase the risk of bleeding when taken concurrently with diclofenac. The official product information should be consulted for a comprehensive list of all potential interactions.

---

Q: What are the most common non-serious side effects of Diclofenaco Pensa?

A: The common side effects that are generally not considered life-threatening include gastrointestinal disturbances, headache, and dizziness. These are typically reported in 1% to 10% of patients.

---

Q: Can I take Diclofenaco Pensa if I'm already taking paracetamol?

A: Official guidance generally does not advise against the use of diclofenac with paracetamol (acetaminophen). However, regulatory warnings strictly advise against taking it with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or aspirin, to avoid an increased risk of adverse events.

---

Q: What are the main therapeutic classes of medicines that interact with Diclofenaco Pensa?

A: The official product information highlights several major therapeutic classes that interact with the medicine. These include blood thinners (anticoagulants), certain antidepressants (SSRIs), diuretics, and medicines for high blood pressure (ACE inhibitors or ARBs).

---

Q: Is Diclofenaco Pensa known to affect blood pressure?

A: Official warnings state that NSAIDs like diclofenac may cause a new onset of high blood pressure (hypertension) or worsen existing high blood pressure. Due to these effects, the product information indicates that the medicine requires careful consideration when used by individuals with existing fluid retention or known high blood pressure.

---

Q: Is it safe to drive a car after taking Diclofenaco Pensa?

A: Due to the possibility of side effects like visual disturbances, dizziness, or drowsiness (somnolence), official safety information advises that activities requiring attention, such as driving or operating machinery, should be avoided if an individual experiences these effects.

---

Q: What happens in the body when Diclofenaco Pensa starts to work?

A: The medicine's primary action is to inhibit cyclooxygenase (COX) enzymes in the body. This blocks the synthesis of prostaglandins—chemical substances that are responsible for initiating pain, inflammation, and fever.

---

Q: Is Diclofenaco Pensa available in different formulations (e.g., tablets, gel)?

A: The active ingredient, diclofenac, is produced in multiple pharmaceutical forms. These can include oral tablets, capsules, and powder for solution, as well as topical preparations like gels and solutions, and injectable forms.

---

Q: Is there any research that supports the use of Diclofenaco Pensa for muscle pain?

A: Official indications show that topical diclofenac is approved for the relief of rheumatic and muscular pain, as well as pain from injuries involving the tendons, ligaments, and muscles. Oral forms are generally approved for various acute pain states.

---

Q: Is there a link between Diclofenaco Pensa and liver function tests?

A: Yes, regulatory warnings note that the medicine has been associated with increases in liver enzyme levels, which are measured by liver function tests. Regular monitoring of liver function is recommended for individuals undergoing prolonged treatment.

---

Q: Is Diclofenaco Pensa prescribed for general body aches and pains?

A: Official documentation indicates that diclofenac is used for the symptomatic relief of pain and inflammation in a wide range of painful conditions. It is used for treating mild-to-moderate pain from various causes.

---

Q: What happens if I miss a dose of Diclofenaco Pensa?

A: Official patient information addresses what to do if a dose is missed, generally advising that a dose should not be doubled. Guidance varies by product, and the specific patient leaflet should be reviewed for instructions.

---

Q: What is Diclofenaco Pensa Pensa used for specifically in dentistry?

A: Diclofenac is approved for the treatment of acute pain. This includes managing acute postsurgical dental pain, particularly the pain that follows common procedures such as wisdom tooth extraction.

---

Q: Is there evidence that Diclofenaco Pensa is more effective for inflammation than pain?

A: Diclofenac is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and an analgesic (pain reliever). Regulatory sources confirm its potent action on both inflammation and pain mechanisms.

---

Q: What are the ingredients in Diclofenaco Pensa besides diclofenac?

A: Every product contains excipients, or inactive ingredients, in addition to the active substance diclofenac. The specific list of excipients, which may include things like cellulose and coating agents, is detailed in the full product label for a specific formulation.

---

Q: Can Diclofenaco Pensa be used for menstrual pain?

A: Yes, official therapeutic indications for diclofenac include the treatment of primary dysmenorrhea, which is the clinical term for menstrual cramps and pain.

---

Q: Does Diclofenaco Pensa interact with common antidepressants?

A: Official drug interaction warnings state that combining diclofenac with Selective Serotonin Reuptake Inhibitors (SSRIs)—a common type of antidepressant—is associated with an increased risk of serious gastrointestinal bleeding.

---

Q: Can Diclofenaco Pensa affect my sleep?

A: The possibility of central nervous system (CNS) side effects is noted in official documentation. These effects include drowsiness, dizziness, and somnolence (sleepiness).

---

Q: Is there specific research on Diclofenaco Pensa's use in sports injuries?

A: Topical diclofenac formulations are approved for treating acute pain resulting from minor soft tissue injuries. This covers common sports-related injuries like strains, sprains, and contusions (bruises).

---

Q: Why is there a warning about kidney issues with Diclofenaco Pensa?

A: Official warnings exist because NSAIDs, including diclofenac, can cause fluid retention. This poses a potential risk for individuals with pre-existing impaired heart or kidney function. For prolonged treatment, monitoring of kidney function is recommended.

---

Q: Is Diclofenaco Pensa considered a strong pain reliever?

A: The medicine is pharmacologically classified as a non-narcotic analgesic and a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is widely used for treating mild to moderate pain.

---

Q: How long does Diclofenaco Pensa stay in my system after the last dose?

A: Regulatory documents state that the terminal plasma half-life of the unchanged medicine is approximately 1 to 2 hours. The medicine and its metabolites are eliminated from the body mainly through urine and bile.

---

Q: Can younger adults typically use Diclofenaco Pensa without issue?

A: Official prescribing information generally advises against use in children and adolescents under 14 years of age. Use in all adults requires careful consideration, especially if there are pre-existing cardiovascular or gastrointestinal risk factors.

The official storage and disposal requirements for Diclofenaco Pensa (Diclofenac oral tablets) are defined by regulatory authorities to preserve product stability and protect the environment.

Official Storage Requirements

Item	Requirement
Temperature	Store at controlled room temperature, typically between 20 C to 25 C. Do not store above 30 C or 25 C, depending on the specific label.
Protection	Protect from moisture and light. Do not refrigerate or freeze the tablets.
Packaging	Keep in the original package or container until ready to use.
Child Safety	Keep out of the sight and reach of children.

Official Disposal Instructions

Item	Requirement
Disposal	Dispose of unused medicinal product or waste material in accordance with local requirements for pharmaceutical waste.
Prohibition	Do not throw away via wastewater or household waste to prevent environmental contamination, particularly of the aquatic environment.